CD276 and acute lymphoblastic leukemia: Our study further suggests that CD276 blockade can relieve the inhibition of NK cell-mediated cytotoxicity likely in BCP-ALL cells with high miR-582 expression, and therefore miR-582 may serve as a biomarker for anti-CD276 therapy of BCP-ALL.